Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for Biote (BTMD) over the last 5 years, with Q3 2025 value amounting to -$690000.0.

  • Biote's Cash from Investing Activities rose 6504.56% to -$690000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.8 million, marking a year-over-year decrease of 48508.95%. This contributed to the annual value of -$18.8 million for FY2024, which is 59288.61% down from last year.
  • As of Q3 2025, Biote's Cash from Investing Activities stood at -$690000.0, which was up 6504.56% from -$2.0 million recorded in Q2 2025.
  • Biote's 5-year Cash from Investing Activities high stood at $316.1 million for Q2 2021, and its period low was -$317.5 million during Q1 2021.
  • Its 5-year average for Cash from Investing Activities is -$1.7 million, with a median of -$1.0 million in 2021.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 620803.86% in 2023, then plummeted by 310421.05% in 2024.
  • Biote's Cash from Investing Activities (Quarter) stood at -$1.0 million in 2021, then skyrocketed by 70.3% to -$311000.0 in 2022, then surged by 6208.04% to $19.0 million in 2023, then tumbled by 106.9% to -$1.3 million in 2024, then surged by 47.37% to -$690000.0 in 2025.
  • Its last three reported values are -$690000.0 in Q3 2025, -$2.0 million for Q2 2025, and -$1.8 million during Q1 2025.